European Medicines Agency accepts marketing application of Biocon, Mylan product
Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Diabetes | Endocrinology | European Medicines Agency (EMA) | Insulin | Lantus | Marketing | Pharmaceuticals